Navigation Links
SemBioSys announces 2007 financial and operational results
Date:3/17/2008

- Canadian Biotechnology Company advances pharmaceutical programs while

executing on non-pharmaceutical opportunities -

TSX symbol: SBS

CALGARY, March 17 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its operational and financial results for the twelve-month period ended December 31, 2007.

"We made progress on multiple product candidates during 2007 that was essential to setting the stage for significant value creating milestones in 2008. We believe that each of our candidates individually represent an exciting and material opportunity to the growth of our company. The basis for this growth is the flexibility of our proprietary oilbody-oleosin technology which allows us to target multiple markets that require high volume, cost-effective pharmaceutical and non-pharmaceutical products," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Establishing Botaneco as a separate operating company with genuine value creating potential and achieving commercially viable levels of Apo AI accumulation were some of the key highlights of the year for us. Additionally, we have made significant progress on the insulin program including the necessary preclinical work to submit an IND in order to begin the Phase I/II clinical trial in the second half of 2008. While we have adjusted the expected start date of the insulin clinical trial, we believe the insulin program represents just one of the important upcoming milestones for SemBioSys in 2008. We also expect in vivo functional and efficacy results from Apo AI(Milano), which has the potential to attract partnership opportunities as well as further growth and business development opportunities from Botaneco. Our recent achievements have also begun to attract interest from new potential partners that believe the capab
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
2. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
3. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys announces 2007 third quarter results
6. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
7. SemBioSys updates Apo AI development program
8. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
11. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to ... in Charlottetown , PEI.  Bioenterprise has ... Island ADAPT Council for the commercialization of agricultural technologies ... working with PEI ADAPT.  They have been at the ... a decade," explains Dave Smardon , President & ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... - Last week, the nation marked the five-year ... research. Those restrictions have unquestionably set back the progress ... , ,When Congress passed legislation that would have lifted ... whose loved ones are suffering from a wide range ...
... After months of speculation, North Prairie Productions, LLC , ... site for a biodiesel plant that will produce 45 million ... construction on the $42 million facility next spring on about ... it will relocate its Waterloo offices. , ,The site ...
... of Lucigen Corp. will receive two prominent visitors on ... grants. , ,C5-6, which will produce enzymes for use in ... of the Bio-Based Industry Initiative of Wisconsin Gov. ... which is part of $1 million in new state funding for ...
Cached Biology Technology:Stem cell research holds the promise for tomorrow 2Stem cell research holds the promise for tomorrow 3Evansville site chosen for biodiesel plant 2Madison business receives $115,000 of new state biofuels funding 2
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... first study to ever explore biological activity in the deepest ... range of capabilities, including eating hydrocarbons and natural gas, and ... the journal PLoS One, showed that a significant ... temperatures near the boiling point of water. "This is ...
... is available in German . , For the first ... cells in order to study them. Instead, whole living cells are ... an immediate 3-D image, thereby closing a gap between conventional microscopic ... the entire cell in one step. This is an advantage over ...
... International businessman and philanthropist Foster Friess has donated $50,000 to ... ovary (SCCO) by the Translational Genomics Research Institute (TGen) and ... donation in memory of Taryn Ritchey, 22, who in 2007 ... strikes women in the prime of life. "Taryn,s dying ...
Cached Biology News:Busy microbial world discovered in deepest ocean crust ever explored 2New microscope reveals ultrastructure of cells 2Businessman-philanthropist assists TGen-VARI study of rare cancer 2Businessman-philanthropist assists TGen-VARI study of rare cancer 3
... For the professional, student, or faculty researcher, the ... accelerate your research and improve the quality of ... is the edge that researchers using LI-COR DNA ... years. The 4300 System is a third generation ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Ideal for biocompatibility testing at various ... of air through a clean heating ... temperature up to 140F. Transparent panels ... shields allow easy access to the ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Biology Products: